Literature DB >> 23473915

Endothelial function and cardiovascular risk in active inflammatory bowel diseases.

Mariabeatrice Principi1, Mario Mastrolonardo, Pietro Scicchitano, Michele Gesualdo, Marco Sassara, Piero Guida, Antongiulio Bucci, Annapaola Zito, Paola Caputo, Francesca Albano, Enzo Ierardi, Alfredo Di Leo, Marco Matteo Ciccone.   

Abstract

BACKGROUND: Endothelial dysfunction has been already reported in inflammatory bowel diseases (IBD). However, case series so far examined were rather heterogeneous as for disease severity and subsets investigated.
OBJECTIVE: We evaluated endothelial dysfunction by brachial artery flow-mediated vasodilatation (FMD), and subclinical atherosclerosis by assessment of common carotid intima-media thickness (CCA-IMT) in a cohort of patients with Crohn's disease (CD) or Ulcerative colitis (UC) in active phase compared to healthy control subjects.
METHODS: Forty-nine patients (mean age 41±16 years), 25 with CD and 23 with UC, and forty controls (mean age 45±15 years) were enrolled. Diagnosis was based on the standard clinical, endoscopic and histological criteria. Disease activity was assessed by Crohn's Disease Activity Index or Disease Activity Index. All patients, were under medical treatment as appropriate.
RESULTS: FMD values were lower in IBD patients than controls (6.1±3.0 vs 8.2±3.4. p=0.003); no difference was seen between UC/CD groups (5.9±3.5 vs 6.3±2.6, p=0.67). No changes in statistical differences occurred after adjustment for age, gender, body mass index and family history of cardiovascular disease. Finally, no differences in IMT values were seen between IBD patients and controls. Disease duration and medical treatment did not affect endothelial function.
CONCLUSIONS: Our study showed a lower FMD in IBD patients. Inflammation and immune response could explain endothelial dysfunction, which is the earliest stage of atherosclerotic process. IBD patients in active phase might therefore be at higher risk for atherosclerosis progression.
Copyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CCA-IMT; CD; CICs; CVD; Cardiovascular risk; Common carotid artery intima-media thickness; Crohn's disease; Endothelial function; FMD; Flow-mediated vasodilatation; IBD; IMT; Inflammatory bowel diseases; NO; UC; Ulcerative colitis; cardiovascular diseases; chronic inflammatory conditions; common carotid intima-media thickness; eNOS; flow-mediated dilatation; inflammatory bowel diseases; intima-media thickness; nitric oxide; nitric synthase

Mesh:

Year:  2013        PMID: 23473915     DOI: 10.1016/j.crohns.2013.02.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  29 in total

1.  Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario.

Authors:  Enzo Ierardi; Claudia Sorrentino; Mariabeatrice Principi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-08       Impact factor: 7.293

Review 2.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

3.  Pulse wave velocity measurement as a marker of arterial stiffness in pediatric inflammatory bowel disease: a pilot study.

Authors:  Eberhard Lurz; Eliane Aeschbacher; Nicholas Carman; Susanne Schibli; Christiane Sokollik; Giacomo D Simonetti
Journal:  Eur J Pediatr       Date:  2017-05-15       Impact factor: 3.183

Review 4.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.

Authors:  José Miranda-Bautista; Celia de Gracia-Fernández; María López-Ibáñez; María Barrientos; Alejandra Gallo-Moltó; Marina González-Arias; Casilda González-Gil; Alicia Díaz-Redondo; Ignacio Marín-Jiménez; Luis Menchén
Journal:  Dig Dis Sci       Date:  2015-02-14       Impact factor: 3.199

6.  Preclinical atherosclerosis in patients with inflammatory bowel diseases: a case-control study.

Authors:  Vincenzo Bruzzese; Giuseppe Palermo; Lorenzo Ridola; Roberto Lorenzetti; Cesare Hassan; Annamaria Izzo; Angelo Zullo
Journal:  Ann Transl Med       Date:  2017-04

Review 7.  Epidemiology, risk factors and management of cardiovascular diseases in IBD.

Authors:  Siddharth Singh; Iftikhar J Kullo; Darrell S Pardi; Edward V Loftus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 8.  A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Authors:  Stacy B Menees; Corey Powell; Jacob Kurlander; Akash Goel; William D Chey
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

9.  Endothelial Cell Response to Fusobacterium nucleatum.

Authors:  Reila Tainá Mendes; Daniel Nguyen; Danielle Stephens; Ferda Pamuk; Daniel Fernandes; Thomas E Van Dyke; Alpdogan Kantarci
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

10.  The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.

Authors:  Tobias M Nowacki; Alan T Remaley; Dominik Bettenworth; Michel Eisenblätter; Thorsten Vowinkel; Felix Becker; Thomas Vogl; Johannes Roth; Uwe J Tietge; Andreas Lügering; Jan Heidemann; Jerzy-Roch Nofer
Journal:  Br J Pharmacol       Date:  2016-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.